Key Highlights
- Phase 3 dosing of canvuparatide in the oPTimize program has commenced.
- One-year open-label extension data showed a 57% responder rate, comparable to 63% at 12 weeks.
- An End-of-Phase-2 meeting with the FDA supported advancing to Phase 3 and a path toward NDA submission.
- Phase 3 dosing began as of August 27, 2026.
Advancing to Phase 3 in Hypoparathyroidism
MBX Biosciences Inc. (NASDAQ:MBX) said on August 27, 2026 that Phase 3 dosing has commenced for canvuparatide (MBX 2109) in hypoparathyroidism, a condition in which the parathyroid glands produce insufficient hormone, disrupting calcium and phosphate balance in the body. The Phase 3 program is being run under the name oPTimize.
Hypoparathyroidism is often managed with calcium and active vitamin D supplementation, an approach that can require frequent monitoring and does not always adequately control symptoms, leaving room for hormone-replacement approaches like canvuparatide that aim to more directly address the underlying deficiency.
Supportive Phase 2 Durability Data
The move to Phase 3 follows Phase 2 data presented at ENDO on June 13, 2026, which showed a 1-year responder rate of 57% in the trial's open-label extension (OLE), a figure the company described as comparable to the 63% responder rate observed at 12 weeks. The relatively similar responder rates at 12 weeks and one year suggest the treatment effect was largely maintained over the longer follow-up period, a durability signal that can matter for a chronic condition requiring ongoing management.
FDA Alignment
Earlier, on March 9, 2026, MBX Biosciences (NASDAQ:MBX) disclosed the outcome of an End-of-Phase-2 (EoP2) meeting with the FDA, which resulted in plans to advance the program into Phase 3 as designed, along with an outlined path toward eventual New Drug Application (NDA) submission.
Market Reaction
MBX Biosciences (NASDAQ:MBX) shares traded at $66.39, down 0.55%, with the company holding a market Capitalization of approximately $3.2 billion.
What is canvuparatide being developed to treat?
Canvuparatide (MBX 2109), developed by MBX Biosciences (NASDAQ:MBX), is being developed to treat hypoparathyroidism.
What did the Phase 2 open-label extension data show?
It showed a 1-year responder rate of 57%, comparable to the 63% responder rate seen at 12 weeks.
Has the FDA weighed in on the Phase 3 design?
Yes, an End-of-Phase-2 meeting with the FDA supported advancing to Phase 3 and outlined a path toward NDA submission.






Please wait processing your request...